Zobrazeno 1 - 10
of 10 025
pro vyhledávání: ''
Autor:
Marion G. Peters, Douglas T. Dieterich, Harry L.A. Janssen, Ira M. Jacobson, Mindie H. Nguyen, Paul J. Martin, Daryl T.-Y. Lau
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:1766-1775
Background and Aims Chronic hepatitis B (CHB) infection remains the most frequent etiology of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite vaccination, substantial numbers of persons have already been infected with
Autor:
Alessandro Armuzzi, Tommaso Schepis, Antonio Gasbarrini, Franco Scaldaferri, Daniela Pugliese, Flavio Caprioli, Giuseppe Privitera, Luigi Larosa, Sara Onali
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e1483-e1487
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receivi
Autor:
Pablo Navarro, Marta Maia Bosca-Watts, Joan Tosca, Miguel Minguez, Marta Revaliente, Rosario Anton, Ana Sanahuja, Carles Suria
Publikováno v:
Gastroenterologia Y Hepatologia
La pandemia por COVID-19 ha supuesto un reto para los países y sus profesionales sanitarios. La entrada viral en el hospedador a través del receptor ACE-2 y una activación excesiva del sistema inmunológico son claves para comprender tanto la inci
Autor:
Julia Nazco-Casariego, Laura Ramos, Fernando Gutiérrez-Nicolás, Raquel De La Barreda, Enrique Quintero, Inmaculada Alonso-Abreu, Javier Ramos-Rodríguez, Marta Carrillo-Palau
Publikováno v:
Gastroenterología y Hepatología (English Edition). 45:335-341
Nonadherence to medication is common in patients with inflammatory bowel disease (IBD) and can result in disease complications, therapy escalation, and the need for corticosteroids. The aim of this study was to assess the adherence to self-administer
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e1192-e1195
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clin
Publikováno v:
Gut and Liver. 16:147-156
Although Helicobacter pylori infection is the most important causative factor for gastric cancer (GC), H. pylori eradication alone does not completely eliminate the GC risk. In addition to H. pylori eradication, other risk factors for GC should be id
Autor:
Marjolein Y.V. Homs, Florian E. Buisman, Adriaan Moelker, Dirk J. Grünhagen, W.F. Filipe, B. Groot Koerkamp, Boris Galjart, Cees Verhoef
Publikováno v:
HPB. 24(3):299-308
Background The practice of adjuvant hepatic arterial infusion chemotherapy (HAIC) for colorectal liver metastasis (CRLM) varies widely. This meta-analysis investigates the effectiveness of adjuvant HAIC and the influence of variations in HAIC treatme
Autor:
Dana J. Lukin, Paul J. Christos, Robert Battat, Waseem Ahmed, Jonathan S. Galati, Ellen Scherl, Anand Kumar, Randy S. Longman
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e361-e379
Background and Aims We conducted a systematic review and meta-analysis to summarize emerging data on the safety and effectiveness of dual biologic therapy in combination or with tofacitinib in patients with refractory inflammatory bowel disease (IBD)
Autor:
Luisa Castro-Laria, Ana M. Sánchez-Migallón, David Busquets, Ana Echarri, Maria Esteve, Federico Argüelles-Arias, R. Vicente, José María Huguet, María Dolores Martín-Arranz, D Ceballos, Francesc Casellas, Jordina Llaó, for Rapida trial investigators, M Navarro-Llavat, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, Santiago García-López, José Miguel Boudet, Gema Díaz
Publikováno v:
Gastroenterología y Hepatología (English Edition). 45:165-176
No studies evaluating the rapidity of response to biological therapies are available for Crohn's disease (CD). The aim of this study was to evaluate rapidity of onset of clinical response and impact on quality of life (QoL) of adalimumab therapy in a
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 12
Clin Gastroenterol Hepatol
Clin Gastroenterol Hepatol
Background & aimsPatients with Crohn's disease (CD) treated with ustekinumab who experience inadequate response, or loss of response after standard induction and/or maintenance dosing may benefit from dose escalation. We conducted a systematic review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6178ce5b3a9a18fa70971346b665ff
https://escholarship.org/uc/item/270528g4
https://escholarship.org/uc/item/270528g4